{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:52:54Z","timestamp":1795020774089,"version":"4.10.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Molecular analysis of actionable driver mutations and somatic copy number alterations (sCNAs) in circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) is increasingly being used to guide personalised medicine in patients with cancer. In previous CTC studies, high numbers of CTCs were needed for successful recovery of individual CTCs for molecular analysis at a time when patients typically have very short survival, limiting clinical applicability. Here, by performing longitudinal analyses of ctDNA and CTCs across a broad range of CTC counts, we hypothesized that CTCs could reveal synergistic and additional genomic information to ctDNA at points when therapeutic interventions could be considered in the follow up of patients with metastatic breast cancer (MBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eight patients underwent serial blood sampling. CTCs were captured via CellSearch-DEPArray from 7.5\u00a0mL (CellSave tubes), while 15\u00a0mL (EDTA tubes) was used for cfDNA extraction. A total of 58 cfDNA samples and 192 CTCs from the 8 patients were compared by shallow whole genome sequencing sWGS and targeted next generation sequencing using custom designed mutation panels (cfDNA; dual barcoding Ion AmpliSeq HD technology (556 hotspots across 24 genes) and CTCs; SingleSeq-compatible AmpliSeq technology across 539 of the 556 (97%) hotspots).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The majority of patient samples showed complementary genomic information in CTCs and ctDNA from the same blood sample. However, genome changes were detected in CTCs from some blood samples that were ctDNA negative despite progression providing actionable information at times when ctDNA analysis was not informative. Across the CTCs and ctDNA, common regions of loss included chromosome 13q14 containing the\n                      <jats:italic>RB1<\/jats:italic>\n                      gene, detected in 3 of 4 patients receiving CDK4\/6 inhibitors and amplification of 17q12 containing the\n                      <jats:italic>ERBB2<\/jats:italic>\n                      gene in 2 of the 7 patients with HER2 negative metastatic disease, suggesting evolution to HER2 positive disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study shows that CTCs provide key information that would have been missed by ctDNA monitoring alone and extends CTC and cfDNA genomic profiling to patients with a broad range of CTC counts for blood-based monitoring of HER2 status and other clinically actionable targets for informing treatment decisions in metastatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15187-5","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:01:34Z","timestamp":1764943294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Rebecca C.","family":"Allsopp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evie","family":"Wren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Nteliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L. T.","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdeep Matharu","family":"Lall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shradha","family":"Bhagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Acheampong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc K.","family":"Wadsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul Charles","family":"Coombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"6","key":"15187_CR1","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524\u201341.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"15187_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cll.2023.03.004","volume":"43","author":"G Jagannathan","year":"2023","unstructured":"Jagannathan G, White MJ, Xian RR, Emens LA, Cimino-Mathews A. A new landscape of testing and therapeutics in metastatic breast cancer. Clin Lab Med. 2023;43(2):299\u2013321.","journal-title":"Clin Lab Med"},{"issue":"22","key":"15187_CR3","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376(22):2109\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"15187_CR4","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/bjc.2011.89","volume":"104","author":"K Page","year":"2011","unstructured":"Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangpratheep C, et al. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011;104(8):1342\u20138.","journal-title":"Br J Cancer"},{"issue":"21","key":"15187_CR5","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","volume":"30","author":"LS Lindstr\u00f6m","year":"2012","unstructured":"Lindstr\u00f6m LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601\u20138.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"15187_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2024.42.16_suppl.1066","volume":"42","author":"S Morganti","year":"2024","unstructured":"Morganti S, Beagan J, D\u2019Ippolito A, Smith K, Hughes ME, Chmielecki J, et al. Novel epigenomic liquid biopsy assay to predict estrogen receptor (ER) status and to infer ER pathway activation in breast cancer. J Clin Oncol. 2024;42(16_suppl):1066.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15187_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208\u201317.","journal-title":"Ann Oncol"},{"issue":"7","key":"15187_CR8","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","volume":"27","author":"P Narayan","year":"2021","unstructured":"Narayan P, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X, et al. FDA approval summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res. 2021;27(7):1842\u20139.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"15187_CR9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","volume":"21","author":"NC Turner","year":"2020","unstructured":"Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296\u2013308.","journal-title":"Lancet Oncol"},{"issue":"4","key":"15187_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.23.00456","volume":"42","author":"FC Bidard","year":"2024","unstructured":"Bidard FC, Kiavue N, Jacot W, Bachelot T, Dureau S, Bourgeois H, et al. Overall survival with circulating tumor cell count-driven choice of therapy in advanced breast cancer: a randomized trial. J Clin Oncol. 2024;42(4):383\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15187_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","volume":"10","author":"T Thomas-Bonafos","year":"2024","unstructured":"Thomas-Bonafos T, Pierga JY, Bidard FC, Cabel L, Kiavue N. Circulating tumor cells in breast cancer: clinical validity and utility. NPJ Breast Cancer. 2024;10(1):103.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"15187_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/clinchem\/hvad144","volume":"70","author":"T Fehm","year":"2024","unstructured":"Fehm T, Mueller V, Banys-Paluchowski M, Fasching PA, Friedl TWP, Hartkopf A, et al. Efficacy of lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells-the DETECT III clinical trial. Clin Chem. 2024;70(1):307\u201318.","journal-title":"Clin Chem"},{"key":"15187_CR13","doi-asserted-by":"crossref","unstructured":"Keup C, Kimmig R, Kasimir-Bauer S. Combinatorial power of cfDNA, CTCs and EVs in Oncology. Diagnostics (Basel). 2022;12(4).","DOI":"10.3390\/diagnostics12040870"},{"issue":"10","key":"15187_CR14","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/s41416-022-01962-9","volume":"127","author":"D Fernandez-Garcia","year":"2022","unstructured":"Fernandez-Garcia D, Nteliopoulos G, Hastings RK, Rushton A, Page K, Allsopp RC, et al. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer. Br J Cancer. 2022;127(10):1858\u201364.","journal-title":"Br J Cancer"},{"issue":"9_Supplement","key":"15187_CR15","doi-asserted-by":"publisher","first-page":"PO1-16-05","DOI":"10.1158\/1538-7445.SABCS23-PO1-16-05","volume":"84","author":"S Kasimir-Bauer","year":"2024","unstructured":"Kasimir-Bauer S, Storbeck M, Andreou I, hauch S, Hoffmann O, Kimmig R, et al. Abstract PO1-16-05: Matched multi-analyte and multi-omic liquid biopsy of cell-free DNA, circulating tumor cells and extracellular vesicles in HER2-positive metastatic breast cancer patients. Cancer Res. 2024;84(9_Supplement):PO1-16-05-PO1-16-05.","journal-title":"Cancer Res"},{"issue":"9","key":"15187_CR16","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/ijc.29265","volume":"136","author":"J Madic","year":"2015","unstructured":"Madic J, Kiialainen A, Bidard FC, Birzele F, Ramey G, Leroy Q, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer. 2015;136(9):2158\u201365.","journal-title":"Int J Cancer"},{"issue":"4","key":"15187_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1158\/1078-0432.CCR-21-3131","volume":"28","author":"HCF Moore","year":"2022","unstructured":"Moore HCF, Barlow WE, Somlo G, Gralow JR, Schott AF, Hayes DF, et al. A randomized trial of fulvestrant, everolimus, and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222. Clin Cancer Res. 2022;28(4):611\u20137.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"15187_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-17-2092","volume":"24","author":"G Rossi","year":"2018","unstructured":"Rossi G, Mu Z, Rademaker AW, Austin LK, Strickland KS, Costa RLB, et al. Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res. 2018;24(3):560\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15187_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1158\/1078-0432.CCR-16-0825","volume":"23","author":"JA Shaw","year":"2017","unstructured":"Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res. 2017;23(1):88\u201396.","journal-title":"Clin Cancer Res"},{"key":"15187_CR20","doi-asserted-by":"crossref","unstructured":"Welter L, Xu L, McKinley D, Dago AE, Prabakar RK, Restrepo-Vassalli S, et al. Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. Cold Spring Harb Mol Case Stud. 2020;6(6).","DOI":"10.1101\/mcs.a005819"},{"key":"15187_CR21","doi-asserted-by":"crossref","unstructured":"Page K, Martinson LJ, Fernandez-Garcia D, Hills A, Gleason KLT, Gray MC, et al. Circulating tumor DNA profiling from breast cancer screening through to metastatic disease. JCO Precis Oncol. 2021;5.","DOI":"10.1200\/PO.20.00522"},{"issue":"5","key":"15187_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/clinchem\/hvac220","volume":"69","author":"RC Allsopp","year":"2023","unstructured":"Allsopp RC, Page K, Ambasager B, Wadsley MK, Acheampong E, Ntereke TP, et al. A rapid, shallow whole genome sequencing workflow applicable to limiting amounts of cell-free DNA. Clin Chem. 2023;69(5):510\u20138.","journal-title":"Clin Chem"},{"issue":"1","key":"15187_CR23","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324.","journal-title":"Nat Commun"},{"issue":"1","key":"15187_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1235-8","volume":"21","author":"D Fernandez-Garcia","year":"2019","unstructured":"Fernandez-Garcia D, Hills A, Page K, Hastings RK, Toghill B, Goddard KS, et al. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res. 2019;21(1):149.","journal-title":"Breast Cancer Res"},{"key":"15187_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3108","author":"W Janni","year":"2025","unstructured":"Janni W, Friedl TW, Yab TC, Bidard F-C, Cristofanilli M, Hayes DF, et al. Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3108.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"15187_CR26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1373\/clinchem.2011.175570","volume":"58","author":"K Pantel","year":"2012","unstructured":"Pantel K, Den\u00e8ve E, Nocca D, Coffy A, Vendrell JP, Maudelonde T, et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012;58(5):936\u201340.","journal-title":"Clin Chem"},{"issue":"1","key":"15187_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41523-022-00445-7","volume":"8","author":"F Roth\u00e9","year":"2022","unstructured":"Roth\u00e9 F, Venet D, Peeters D, Rouas G, Rediti M, Smeets D, et al. Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. NPJ Breast Cancer. 2022;8(1):79.","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"15187_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","volume":"32","author":"LR Yates","year":"2017","unstructured":"Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, et al. Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell. 2017;32(2):169-84.e7.","journal-title":"Cancer Cell"},{"key":"15187_CR29","doi-asserted-by":"publisher","first-page":"1148792","DOI":"10.3389\/fcell.2023.1148792","volume":"11","author":"FH Zhou","year":"2023","unstructured":"Zhou FH, Downton T, Freelander A, Hurwitz J, Caldon CE, Lim E. CDK4\/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Front Cell Dev Biol. 2023;11:1148792.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"15187_CR30","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.21873\/anticanres.16732","volume":"43","author":"CM Chang","year":"2023","unstructured":"Chang CM, Lam HYP. Mechanism of CDK4\/6 inhibitor resistance in hormone receptor-positive breast cancer and alternative treatment strategies. Anticancer Res. 2023;43(12):5283\u201398.","journal-title":"Anticancer Res"},{"issue":"9","key":"15187_CR31","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1078-0432.CCR-22-2177","volume":"29","author":"AA Davis","year":"2023","unstructured":"Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, et al. Genomic complexity predicts resistance to endocrine therapy and CDK4\/6 inhibition in hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer. Clin Cancer Res. 2023;29(9):1719\u201329.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"15187_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","volume":"14","author":"B Kingston","year":"2024","unstructured":"Kingston B, Pearson A, Herrera-Abreu MT, Sim LX, Cutts RJ, Shah H, et al. ESR1 f404 mutations and acquired resistance to Fulvestrant in ESR1-mutant breast cancer. Cancer Discov. 2024;14(2):274\u201389.","journal-title":"Cancer Discov"},{"issue":"1","key":"15187_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a phase I study of the CDK7-inhibitor samuraciclib. Nat Commun. 2023;14(1):4444.","journal-title":"Nat Commun"},{"issue":"25","key":"15187_CR34","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"48","key":"15187_CR35","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1038\/s41388-023-02839-8","volume":"42","author":"C Callens","year":"2023","unstructured":"Callens C, Rodrigues M, Briaux A, Frouin E, Eeckhoutte A, Pujade-Lauraine E, et al. Shallow whole genome sequencing approach to detect homologous recombination deficiency in the PAOLA-1\/ENGOT-OV25 phase-III trial. Oncogene. 2023;42(48):3556\u201363.","journal-title":"Oncogene"},{"issue":"1","key":"15187_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03296-x","volume":"5","author":"G Bianco","year":"2022","unstructured":"Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, et al. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Commun Biol. 2022;5(1):373.","journal-title":"Commun Biol"},{"issue":"1","key":"15187_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-025-07606-x","volume":"8","author":"A Ghosh","year":"2025","unstructured":"Ghosh A, Chaubal R, Das C, Parab P, Das S, Maitra A, et al. Genomic hallmarks of endocrine therapy resistance in ER\/PR+HER2- breast tumours. Commun Biol. 2025;8(1):207.","journal-title":"Commun Biol"},{"issue":"5","key":"15187_CR38","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00432-019-02873-8","volume":"145","author":"X Chen","year":"2019","unstructured":"Chen X, Guo Y, Ouyang T, Li J, Wang T, Fan Z, et al. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer. J Cancer Res Clin Oncol. 2019;145(5):1235\u201342.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"15187_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377\u201386.","journal-title":"Ann Oncol"},{"issue":"4","key":"15187_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","volume":"15","author":"FC Bidard","year":"2014","unstructured":"Bidard FC, Peeters DJ, Fehm T, Nol\u00e9 F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406\u201314.","journal-title":"Lancet Oncol"},{"issue":"18","key":"15187_CR41","doi-asserted-by":"publisher","first-page":"7357","DOI":"10.1158\/0008-5472.CAN-09-0064","volume":"69","author":"M Kadota","year":"2009","unstructured":"Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res. 2009;69(18):7357\u201365.","journal-title":"Cancer Res"},{"issue":"7","key":"15187_CR42","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, Im SA, Iwata H, Cort\u00e9s J, De Laurentiis M, Jiang Z, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904\u201316.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15187_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","volume":"19","author":"A Di Leo","year":"2018","unstructured":"Di Leo A, Johnston S, Lee KS, Ciruelos E, L\u00f8nning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87\u2013100.","journal-title":"Lancet Oncol"},{"issue":"14","key":"15187_CR44","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-20-4879","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma P, Abramson VG, O\u2019Dea A, Nye L, Mayer I, Pathak HB, et al. Clinical and biomarker results from phase I\/II study of PI3K inhibitor Alpelisib plus Nab-paclitaxel in HER2-negative metastatic breast cancer. Clin Cancer Res. 2021;27(14):3896\u2013904.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"15187_CR45","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","volume":"1","author":"P Razavi","year":"2020","unstructured":"Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020;1(4):382\u201393.","journal-title":"Nat Cancer"},{"issue":"4","key":"15187_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s12276-023-00979-1","volume":"55","author":"J Kwon","year":"2023","unstructured":"Kwon J, Lee D, Lee SA. BAP1 as a guardian of genome stability: implications in human cancer. Exp Mol Med. 2023;55(4):745\u201354.","journal-title":"Exp Mol Med"},{"issue":"7","key":"15187_CR47","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","volume":"44","author":"S Pe\u00f1a-Llopis","year":"2012","unstructured":"Pe\u00f1a-Llopis S, Vega-Rub\u00edn-de-Celis S, Liao A, Leng N, Pav\u00eda-Jim\u00e9nez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751\u20139.","journal-title":"Nat Genet"},{"issue":"2","key":"15187_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2023;22(2):127\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"15187_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92.","journal-title":"Signal Transduct Target Ther"},{"issue":"16_suppl","key":"15187_CR50","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.2023.41.16_suppl.4009","volume":"41","author":"MJ Borad","year":"2023","unstructured":"Borad MJ, Schram AM, Kim RD, Kamath SD, Sahai V, Dotan E, et al. Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors. J Clin Oncol. 2023;41(16_suppl):4009.","journal-title":"J Clin Oncol"},{"issue":"6","key":"15187_CR51","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","volume":"30","author":"J Rod\u00f3n","year":"2024","unstructured":"Rod\u00f3n J, Damian S, Furqan M, Garc\u00eda-Donas J, Imai H, Italiano A, et al. Pemigatinib in previously treated solid tumors with activating FGFR1\u2013FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat Med. 2024;30(6):1645\u201354.","journal-title":"Nat Med"},{"issue":"1","key":"15187_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","volume":"54","author":"S Ahn","year":"2020","unstructured":"Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34\u201344.","journal-title":"J Pathol Transl Med"},{"issue":"2","key":"15187_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discovery. 2023;22(2):101\u201326.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"15187_CR54","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373.","journal-title":"Nat Commun"},{"issue":"22","key":"15187_CR55","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1158\/1078-0432.CCR-19-3958","volume":"26","author":"P Mao","year":"2020","unstructured":"Mao P, Cohen O, Kowalski KJ, Kusiel JG, Buendia-Buendia JE, Cuoco MS, et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER(+) metastatic breast cancer. Clin Cancer Res. 2020;26(22):5974\u201389.","journal-title":"Clin Cancer Res"},{"key":"15187_CR56","doi-asserted-by":"crossref","unstructured":"Bourrier C, Pierga JY, Xuereb L, Salaun H, Proudhon C, Speicher MR, et al. Shallow whole-genome sequencing from plasma identifies FGFR1 amplified breast cancers and predicts overall survival. Cancers (Basel). 2020;12(6).","DOI":"10.3390\/cancers12061481"},{"issue":"1","key":"15187_CR57","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1038\/s41467-022-30666-0","volume":"13","author":"RC Coombes","year":"2022","unstructured":"Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, et al. Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun. 2022;13(1):3246.","journal-title":"Nat Commun"},{"issue":"1","key":"15187_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","volume":"17","author":"P Zhang","year":"2024","unstructured":"Zhang P, Yue L, Leng Q, Chang C, Gan C, Ye T, et al. Targeting FGFR for cancer therapy. J Hematol Oncol. 2024;17(1):39.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"15187_CR59","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1541-7786.MCR-21-0402","volume":"20","author":"JF Xiao","year":"2022","unstructured":"Xiao JF, Kua LF, Ding LW, Sun QY, Myint KN, Chia XR, et al. KDM6A depletion in breast epithelial cells leads to reduced sensitivity to anticancer agents and increased TGF\u03b2 activity. Mol Cancer Res. 2022;20(4):637\u201349.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"15187_CR60","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1186\/bcr3647","volume":"16","author":"M Ignatiadis","year":"2014","unstructured":"Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Roth\u00e9 F, et al. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res. 2014;16(2):R43.","journal-title":"Breast Cancer Res"},{"key":"15187_CR61","doi-asserted-by":"publisher","first-page":"100135","DOI":"10.1016\/j.jlb.2023.100135","volume":"3","author":"A Auwal","year":"2024","unstructured":"Auwal A, Hossain MM, Pronoy TUH, Rashel KM, Nurujjaman M, Lam AKY, et al. Clinical significance of genomic sequencing of circulating tumour cells (CTCs) in cancer. The Journal of Liquid Biopsy. 2024;3:100135.","journal-title":"The Journal of Liquid Biopsy"},{"key":"15187_CR62","doi-asserted-by":"publisher","first-page":"101258","DOI":"10.1016\/j.mam.2024.101258","volume":"96","author":"DJ Smit","year":"2024","unstructured":"Smit DJ, Pantel K. Circulating tumor cells as liquid biopsy markers in cancer patients. Mol Aspects Med. 2024;96:101258.","journal-title":"Mol Aspects Med"},{"key":"15187_CR63","doi-asserted-by":"crossref","unstructured":"Yadav, MCLKVGRALFJLCMPGTCHDRSS, editor. Abstract 3119: Comparison of circulating tumor cell (CTC) derived DNA and circulating cell-free DNA (cfDNA) from simultaneous blood sampling of patients with metastatic breast cancer (MBC). Philadelphia: American Association for Cancer Research; 2020.","DOI":"10.1158\/1538-7445.AM2020-3119"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15187-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15187-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:03:45Z","timestamp":1764947025000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15187-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15187"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15187-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Riverside Research Ethics Committee (Imperial College Healthcare NHS Trust), Tissue Bank Ethics\/REC reference 22\/WA\/0214 and was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1858"}}